Skip to Navigation
Company JW KEEPING THE HEALTH AND FUTURE OF HUMANKIND

History

JW Group has started its steps with the restoration of nation’s independence

JW Group’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.
  • 2021
    • Completion of a phase 2b clinical trial of the anti-gout drug URC102
    • Enter a phase 2b dose-ranging clinical trial of the new atopic dermatitis drug candidate JW1601
    • Signed a non-cxclusive license agreement with Immunovia(Sweden) for the patent 'diagnostic biomarker of pancreatic cancer'
    • World's 1st Europeon&Chinese patent registration of diagnostic technique for sepsis
    • Signed a license agreement for Fostamatinib with Kissei Pharmaceutical Co.,Ltd.
    • The cumulative output of IV product exceed 3 billion
  • 2020
    • Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
    • Joint development of a next-generation nutrient sap with Baxter
    • Conclusion of the Winuf® exclusive technology exportation and provision agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in China
  • 2019
    • C&C Research Laboratories, JW Pharmaceutical Subsidiary transfer
    • Signed a technology export contract with the Simcere
      company in China,'URC102' for gout treatment
    • Acquired 'Euvipharm', the first Vietnamese pharmaceutical
      company in Korea
    • Atopic dermatitis ‘JW1601’ won the ‘Technology Exporter’
      and the 'King Sejong the Great', the highest patented
      technology in Korea
    • Acquired patents for China and Europe for early diagnosis
      of pancreatic cancer
    • A hemophilia drug 'hemri Bra' rare drug designation and
      market sales permit
    • Asia’s first sell a three-chamber nutrient infusion in EU
  • 2018
    • JW Life Science Industry First "Nutrient Toolking" in Asia Get EU
      – GMP
    • Technology export of atopic dermatitis drug 'JW1601'
  • 2017
    • 2017 Signed export contract for ‘Ertapenem’,
      the next generation antibiotic with Gland Pharma from India
  • 2016
    • JW Lifescience listed on Securities Market
  • 2015
    • Vision 70+5 Declaration
  • 2013
    • Signed Export Agreement with America’s Baxter for 3-Chamber
      Nourishment Transfusion Fluid
    • Joint-Development agreement with Japan’s SKK worth 100 billion
      for pharmaceutical products
    • Founded True Medical Personnel respecting life,
      enacted ‘Sungcheon Award’
  • 2012
    • Relocation of C&C new medicine research institute
    • (DRC hall, Sungkyunkwan University,
      Suwon natural science campus)
  • 2011
    • Renamed to JW Holdings Corporation
    • Renamed to JW Pharmaceutical Corporation
    • Renamed to JW Shinyak Corporation
    • Renamed to JW Life Science Corporation
    • Renamed to JW Medical Corporation
    • Renamed to JW Living Healthcare Corporation
  • 2010
    • JW Dangjin Production Complex, which is Korea’s largest
      Medicine-manufacturing plant, was built
  • 2009
    • JW Shinyak was listed on the KOSDAQ
    • Awarded US$30 mil-Export Tower
  • 2008
    • Took over Three-Seven
    • Certified as Good Labor Culture Enterprise from Labor Ministry
    • Eco-friendly B1 established
  • 2007
    • Awarded Presidential Citation on the occasion of Environment Day
    • Choongwae Holdings established
  • 2006
    • World’s largest Non-PVC supplement plant (Dangjin) was built
  • 2005
    • Designated as Korea’s 30-respectable enterprises
    • (Dong-A Ilbo Daily, IBM BCS)
    • Designated as Asia’s 200 outstanding enterprises (Fobes Asia)
    • Choongwae Shinyak established
  • 2004
    • Antibiotics, ‘Impenem’ first generic with US$600 mil-scale potential
    • Global market developed
    • Impenem plant meeting EU GMP standard was built (Sihwa)
  • 2003
    • Awarded the 3rd Gyeonggi Green Environment Trophy
      (Gyeonggi Province)
    • Awarded the 4th Korea Business Image Grand Prize by KMAC
    • Awarded the 5th Industrial Peace Grand Prize
  • 2002
    • Awarded New Medicine Development Prize with Balofloxacin
      (Ginko biloba leaf extract)
    • Antibiotics Ketoconnazole was certified by Europe COS

JW Group has started its steps with the restoration of nation’s independence

JW Group’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.
  • 2001
    • Awarded the 1st CEO grand prize (Korea CEO Academy)
    • Balofloxacin certified by KFDA
      as Phase Ⅲ shinyak for the first time in Korea
  • 2000
    • Awarded US$10mil Export Tower
    • Theriac Research Corporation established
      (Joint research agreement with PNRI)
  • 1999
    • Hydration solution production exceeded 1 billion bottles
    • Choongwae Information Technology (CIT) established
  • 1998
    • Designated as Good Pharmaceutical company
      (Medical Paper, Ilgan Bosa)
    • Awarded the 5th Foundation Prize (KASBA)
  • 1997
    • Designated as Good Labor-Management relationship company
      (Labor Ministry)
    • Antifungal Itraconazole developed
  • 1995
    • Awarded the 4th Economy Righteousness Enterprise
    • Awarded Industrial Bronze Tower
  • 1994
    • Designated as Good Environment Enterprise for 3 consecutive years
    • Choongwae Chemcal established
    • Arthythima treatment medicine, KCB, developed
  • 1993
    • JW Medical established by meeting
      Choongwae Machinery and Choongwae trading company
  • 1992
    • C&C Research & Lab established
  • 1991
    • Chungmo Pharmaceutical renamed to Daeyoo Pharmaceutical
    • Designated as eligible KGMP company (Health Ministry)
  • 1990
    • Chungmo Pharmaceutical merged
    • Awarded Moran Medal
  • 1988
    • Choongwae Industrial established
  • 1987
    • Choongwae Medical Corp’s Yongin plan completed
    • Designated as KGMP eligible company (Health Ministry)
    • Awarded Moran Medal

JW Group has started its steps with the restoration of nation’s independence

JW Group’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.
  • 1986
    • Head office moved to 698. Shindaebang-dong, Dongjaak-gu, Seoul
  • 1984
    • Awarded Saemaeul Hyunpdong Medal
  • 1983
    • General R&D institute established: Designated as subsidiary intitute
      By the Ministry of Science and Technology
  • 1982
    • Renamed to Choongwae Pharmaceutical
  • 1977
    • Factory built at 146-141,
      Annyung-ri, Taean-eup, Hwansung-gun, Gyeonggi province
    • Choongwae machinery established
  • 1976
    • Initial Public Offering :
      capital 800 mil-Listed on the stock market
  • 1975
    • JGMP-based manufacture and inspection record system established
      (for the first time in Korea)
  • 1972
    • Daehan Choongwae Corp established
  • 1969
    • Awarded Invention Prize
      (development of TC water soluble Derivative
      (Lymecycline HCL)
  • 1953
    • Daehan Choongwae Medical Corp established
  • 1945
    • Joseon Choongwae Pharmaceutical established
      (at 3-ga, Choongmuro, Seoul)